MarketCap
Facebook
X
Telegram
Zynerba Pharmaceuticals Income Statement 2022-2011 | ZYNE
Brief overview of income trends at Zynerba Pharmaceuticals
The overview follows changes across a five-year period. Revenue reported by Zynerba Pharmaceuticals was 944 thousand dollars at the beginning of the period and 86 thousand dollars at the end. The cumulative result was −90.9%, corresponding to roughly −38.1% per year. The decline points to a contraction in the scale of the business.
EBITDA was −585 thousand dollars at the beginning and −40.3 million dollars at the end of the period (−6788%). EBITDA underperformed the top-line trend. EBITDA margin was −62% at the start and −46858.4% at the end. The margin contraction indicates weaker operating efficiency.
The net financial result changed from −637 thousand dollars to −39.9 million dollars. The negative result deepened, showing weaker final efficiency.
Overall conclusion
The results contain several connected negative signals. The main areas of concern are a softer top-line trend, a low EBITDA margin and pressure on operating profitability. Future reports should be judged by revenue momentum, margins, and the conversion of sales into net income.
Annual Income Statement Zynerba Pharmaceuticals
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Market Cap |
18.8 M | 102 M | 94.3 M | 111 M | 80.2 M | 156 M | 156 M | 29.5 M | - | - | - | - |
Shares |
42.7 M | 39.3 M | 27 M | 22 M | 15.3 M | 12.9 M | 9.07 M | 4.46 M | 895 K | 491 K | - | - |
Historical Prices |
0.44 | 2.61 | 3.49 | 5.04 | 5.24 | 12.1 | 17.2 | 6.62 | - | - | - | - |
Net Income |
-35 M | -37.3 M | -51.3 M | -32.9 M | -39.9 M | -32 M | -23.4 M | -12.6 M | -5.67 M | -637 K | - | - |
Revenue |
- | - | - | - | 86 K | - | 7.25 K | 279 K | 810 K | 944 K | - | - |
Gross Profit |
- | - | - | - | - | - | - | 279 K | 810 K | 944 K | - | - |
Operating Income |
-35.3 M | -36.8 M | -52.1 M | -34.3 M | -40.4 M | -32.8 M | -23.2 M | -12.5 M | -5.67 M | -634 K | - | - |
Interest Expense |
- | - | - | - | - | - | 27 K | 4.4 K | -1.84 K | -2.35 K | - | - |
EBITDA |
-35 M | -36.5 M | -51.9 M | -34.2 M | -40.3 M | -32.7 M | -23.1 M | -12.5 M | -5.64 M | -585 K | - | - |
Operating Expenses |
35.3 M | 36.8 M | 52.1 M | 34.3 M | 40.5 M | 32.8 M | 23.2 M | 12.8 M | 6.48 M | 1.58 M | - | - |
General and Administrative Expenses |
14.2 M | 15.3 M | 16.4 M | 13.9 M | 13.2 M | 10 M | 6.43 M | 5.36 M | 4.08 M | 444 K | - | - |
All numbers in USD currency
Quarterly Income Statement Zynerba Pharmaceuticals
| 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Shares |
50.2 M | 48.4 M | 47.9 M | 43.7 M | 41.4 M | 40.3 M | 41.2 M | 40.1 M | 40.1 M | 40.1 M | 29.3 M | 29.2 M | 26.1 M | 23.4 M | 23.2 M | 23.2 M | 22.1 M | 19.5 M | 17.6 M | 16.6 M | 13.5 M | 13.5 M | 13.4 M | 13.1 M | 13.1 M | 12.1 M | 9.68 M | 8.91 M | 8.86 M | 8.82 M | 8.79 M | 6.05 M | 2.03 M | 1.45 M | 1.46 M | 954 K | 660 K | 491 K | - | - | - | - | - | - | - | - | - | - | - | - |
Net Income |
-10.8 M | -10.1 M | - | -8.68 M | -9.85 M | -8.49 M | - | -10.6 M | -9.95 M | -7.96 M | -9.62 M | -9.05 M | -20.3 M | -12.3 M | -10.7 M | -1.95 M | -11.1 M | -9.15 M | -7.79 M | -32.1 M | -24.3 M | -12.3 M | -8.12 M | -8.31 M | -8.32 M | -7.26 M | -6.9 M | -5.98 M | -6.23 M | -4.28 M | -5.44 M | -3.99 M | -1.63 M | -1.49 M | -1.4 M | -2.52 M | -1.51 M | -240 K | - | - | - | - | - | - | - | - | - | - | - | - |
Revenue |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 86 K | - | - | - | - | - | - | - | - | - | - | 7.25 K | 49.3 K | 199 K | 15.4 K | 14.8 K | 74.2 K | 525 K | 64.1 K | 146 K | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Income |
-11.1 M | -10.5 M | - | -8.49 M | -9.17 M | -8.9 M | - | -10.2 M | -9.84 M | -7.88 M | -10.2 M | -9.23 M | -21.8 M | -10.8 M | -11.4 M | -1.93 M | -11.5 M | -9.47 M | -8.05 M | -7.99 M | -12 M | -12.4 M | -8.2 M | -8.55 M | -8.37 M | -7.7 M | -6.68 M | -6 M | -6.28 M | -4.24 M | -5.42 M | -4 M | -1.63 M | -1.49 M | -1.4 M | -2.51 M | -1.51 M | -239 K | - | - | - | - | - | - | - | - | - | - | - | - |
Interest Expense |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 76.9 K | 27 K | 22.7 K | -2.13 K | -10.8 K | 4.4 K | 1.57 K | 697 | 680 | - | -359 | -268 | -1.22 K | - | - | - | - | - | - | - | - | - | - | - | - |
EBITDA |
-11 M | -10.4 M | - | -8.33 M | -9.05 M | -8.84 M | - | -10 M | -9.72 M | -7.82 M | -10.2 M | -9.17 M | -21.8 M | -10.8 M | -11.4 M | -1.89 M | -11.5 M | -9.44 M | -8.05 M | -7.96 M | -11.9 M | -12.4 M | -8.2 M | -8.52 M | -8.34 M | -7.68 M | -6.68 M | -5.97 M | -6.27 M | -4.23 M | -5.42 M | -3.99 M | -1.62 M | -1.49 M | -1.4 M | -2.51 M | -1.5 M | -239 K | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Expenses |
11.1 M | 10.5 M | - | 8.49 M | 9.17 M | 8.9 M | - | 10.2 M | 9.84 M | 7.88 M | 10.2 M | 9.23 M | 21.8 M | 10.8 M | 11.4 M | 1.93 M | 11.5 M | 9.47 M | 8.13 M | 7.99 M | 12 M | 12.4 M | 8.2 M | 8.55 M | 8.37 M | 7.7 M | 6.68 M | 6 M | 6.28 M | 4.25 M | 5.47 M | 4.19 M | 1.64 M | 1.51 M | 1.48 M | 3.04 M | 1.57 M | 385 K | - | - | - | - | - | - | - | - | - | - | - | - |
General and Administrative Expenses |
3.97 M | 3.39 M | - | 3.45 M | 3.72 M | 3.76 M | - | 3.87 M | 4.39 M | 3.28 M | 4.57 M | 3.43 M | 4.49 M | 3.92 M | 3.96 M | 3.53 M | 3.29 M | 3.16 M | 3.26 M | 3.13 M | 3.44 M | 3.42 M | 2.38 M | 2.8 M | 2.63 M | 2.21 M | 1.78 M | 1.49 M | 1.48 M | 1.68 M | 2.16 M | 1.92 M | 631 K | 654 K | 663 K | 2.11 M | 1.21 M | 99.7 K | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
The income statement is one of the three key financial reports of a company Zynerba Pharmaceuticals (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:
- How much revenue the company earned
- How much it spent on production, personnel, marketing, taxes, etc.
- What profit remained in the end
Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.
Features- The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
- Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
- A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.
Canada
USA
Schweden
China
France
Irlanda
